Cargando…

Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation

In malignant cancer, excessive amounts of mutant p53 often lead to its aggregation, a feature that was recently identified as druggable. Here, we describe that induction of a heat shock-related stress response mediated by Foldlin, a small-molecule tool compound, reduces the protein levels of misfold...

Descripción completa

Detalles Bibliográficos
Autores principales: Naus, Evelyne, Derweduwe, Marleen, Lampi, Youlia, Claeys, Annelies, Pauwels, Jarne, Langenberg, Tobias, Claes, Filip, Xu, Jie, Haemels, Veerle, Atak, Zeynep Kalender, van der Kant, Rob, Van Durme, Joost, De Baets, Greet, Ligon, Keith L., Fiers, Mark, Gevaert, Kris, Aerts, Stein, Rousseau, Frederic, Schymkowitz, Joost, De Smet, Frederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047295/
https://www.ncbi.nlm.nih.gov/pubmed/36980299
http://dx.doi.org/10.3390/cells12060960
_version_ 1785013885095378944
author Naus, Evelyne
Derweduwe, Marleen
Lampi, Youlia
Claeys, Annelies
Pauwels, Jarne
Langenberg, Tobias
Claes, Filip
Xu, Jie
Haemels, Veerle
Atak, Zeynep Kalender
van der Kant, Rob
Van Durme, Joost
De Baets, Greet
Ligon, Keith L.
Fiers, Mark
Gevaert, Kris
Aerts, Stein
Rousseau, Frederic
Schymkowitz, Joost
De Smet, Frederik
author_facet Naus, Evelyne
Derweduwe, Marleen
Lampi, Youlia
Claeys, Annelies
Pauwels, Jarne
Langenberg, Tobias
Claes, Filip
Xu, Jie
Haemels, Veerle
Atak, Zeynep Kalender
van der Kant, Rob
Van Durme, Joost
De Baets, Greet
Ligon, Keith L.
Fiers, Mark
Gevaert, Kris
Aerts, Stein
Rousseau, Frederic
Schymkowitz, Joost
De Smet, Frederik
author_sort Naus, Evelyne
collection PubMed
description In malignant cancer, excessive amounts of mutant p53 often lead to its aggregation, a feature that was recently identified as druggable. Here, we describe that induction of a heat shock-related stress response mediated by Foldlin, a small-molecule tool compound, reduces the protein levels of misfolded/aggregated mutant p53, while contact mutants or wild-type p53 remain largely unaffected. Foldlin also prevented the formation of stress-induced p53 nuclear inclusion bodies. Despite our inability to identify a specific molecular target, Foldlin also reduced protein levels of aggregating SOD1 variants. Finally, by screening a library of 778 FDA-approved compounds for their ability to reduce misfolded mutant p53, we identified the proteasome inhibitor Bortezomib with similar cellular effects as Foldlin. Overall, the induction of a cellular heat shock response seems to be an effective strategy to deal with pathological protein aggregation. It remains to be seen however, how this strategy can be translated to a clinical setting.
format Online
Article
Text
id pubmed-10047295
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100472952023-03-29 Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation Naus, Evelyne Derweduwe, Marleen Lampi, Youlia Claeys, Annelies Pauwels, Jarne Langenberg, Tobias Claes, Filip Xu, Jie Haemels, Veerle Atak, Zeynep Kalender van der Kant, Rob Van Durme, Joost De Baets, Greet Ligon, Keith L. Fiers, Mark Gevaert, Kris Aerts, Stein Rousseau, Frederic Schymkowitz, Joost De Smet, Frederik Cells Article In malignant cancer, excessive amounts of mutant p53 often lead to its aggregation, a feature that was recently identified as druggable. Here, we describe that induction of a heat shock-related stress response mediated by Foldlin, a small-molecule tool compound, reduces the protein levels of misfolded/aggregated mutant p53, while contact mutants or wild-type p53 remain largely unaffected. Foldlin also prevented the formation of stress-induced p53 nuclear inclusion bodies. Despite our inability to identify a specific molecular target, Foldlin also reduced protein levels of aggregating SOD1 variants. Finally, by screening a library of 778 FDA-approved compounds for their ability to reduce misfolded mutant p53, we identified the proteasome inhibitor Bortezomib with similar cellular effects as Foldlin. Overall, the induction of a cellular heat shock response seems to be an effective strategy to deal with pathological protein aggregation. It remains to be seen however, how this strategy can be translated to a clinical setting. MDPI 2023-03-21 /pmc/articles/PMC10047295/ /pubmed/36980299 http://dx.doi.org/10.3390/cells12060960 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Naus, Evelyne
Derweduwe, Marleen
Lampi, Youlia
Claeys, Annelies
Pauwels, Jarne
Langenberg, Tobias
Claes, Filip
Xu, Jie
Haemels, Veerle
Atak, Zeynep Kalender
van der Kant, Rob
Van Durme, Joost
De Baets, Greet
Ligon, Keith L.
Fiers, Mark
Gevaert, Kris
Aerts, Stein
Rousseau, Frederic
Schymkowitz, Joost
De Smet, Frederik
Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation
title Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation
title_full Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation
title_fullStr Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation
title_full_unstemmed Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation
title_short Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation
title_sort reduced levels of misfolded and aggregated mutant p53 by proteostatic activation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047295/
https://www.ncbi.nlm.nih.gov/pubmed/36980299
http://dx.doi.org/10.3390/cells12060960
work_keys_str_mv AT nausevelyne reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT derweduwemarleen reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT lampiyoulia reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT claeysannelies reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT pauwelsjarne reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT langenbergtobias reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT claesfilip reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT xujie reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT haemelsveerle reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT atakzeynepkalender reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT vanderkantrob reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT vandurmejoost reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT debaetsgreet reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT ligonkeithl reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT fiersmark reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT gevaertkris reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT aertsstein reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT rousseaufrederic reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT schymkowitzjoost reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation
AT desmetfrederik reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation